Arrowhead Pharmaceuticals Stock Forecast, Price & News

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARWR shares have increased by 126.4% and is now trading at $64.65.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arrowhead Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Sunday, November, 22nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.34 by $0.82. Arrowhead Pharmaceuticals had a negative return on equity of 17.37% and a negative net margin of 96.09%.
View Arrowhead Pharmaceuticals' earnings history.

12 analysts have issued 1 year target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $98.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $75.46 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals.

Some companies that are related to Arrowhead Pharmaceuticals include Genmab A/S (GMAB), Genmab A/S (GNMSF), BeiGene (BGNE), UCB (UCBJF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), Royalty Pharma (RPRX), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Grifols (GRFS) and MyoKardia (MYOK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), State Street Corp (4.44%), JPMorgan Chase & Co. (1.43%), Point72 Asset Management L.P. (1.30%), Charles Schwab Investment Management Inc. (0.89%) and Morgan Stanley (0.50%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien, William D Waddill and Zhen Li.
View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, AQR Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Candriam Luxembourg S.C.A., AXA S.A., Natixis, and Hussman Strategic Advisors Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, and Patrick O'brien.
View insider buying and selling activity for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, First Light Asset Management LLC, Charles Schwab Investment Management Inc., Point72 Asset Management L.P., Retirement Systems of Alabama, Castleark Management LLC, and Tygh Capital Management Inc..
View insider buying and selling activity for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $64.65.

Arrowhead Pharmaceuticals has a market capitalization of $6.64 billion and generates $87.99 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or ($0.84) on an earnings per share basis. Arrowhead Pharmaceuticals employs 134 workers across the globe.

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]